Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$86.77
▼ $0.75 (-0.9%)
Market data updated: 09/17 03:29 AM
Fundamentals updated: 09/17/2026
News analyzed: 09/17/2026
Market Cap
$9.67B
Day Range
$86.44 - $88.32
52-Week Range
$61.95 - $92.18
Beta
—
Next Earnings
02.11.2026
HSIC is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+26.9% (1Y)
Strengths: 3/29 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🟡 Mixed
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Daily volatility (ATR)
ATR: 2.0% of price
Risk
Biggest negative driver
Operating margin stability
Operating margin is eroding over time
Quality
What to watch next
When today echoes the past.
84/100
Similarity
15
Historical Matches
92/100
Analog Quality
-2.0%
Median 40D Outcome
72/100
Pattern Consistency
🟢 Bullish
40%
+2.8% … +5.9%
🟡 Base
0%
— … —
🔴 Bearish
60%
-8.2% … -3.1%
Typical timeframe (based on real historical rates clearing a 60% bar): 20 trading days.
📌 Bottom line: Out of 15 similar historical cases for this stock, 40% (95% CI 20%–64%) saw the stock rise within 20 trading days, with a median gain of -3.1%.
Echo #1 — Momentum Breakout
6 occurrence(s) · 50% historical success
Echo #2 — Trend Acceleration
2 occurrence(s) · 50% historical success
Historical outcome rate is not a probability — it's what happened in this specific historical sample, with a 95% confidence range.
| Horizon | Positive rate (95% CI) | Median | 25th–75th pct | Baseline median |
|---|---|---|---|---|
| 5D | 27% (11%–52%) | -0.3% | -3.9% … +1.1% | +0.1% |
| 10D | 33% (15%–58%) | +0.3% | -3.6% … +1.7% | +0.2% |
| 20D | 40% (20%–64%) | -3.1% | -3.5% … +2.9% | +0.5% |
| 40D | 27% (11%–52%) | -2.0% | -5.6% … +1.2% | +0.7% |
| 60D | 20% (7%–45%) | -4.9% | -10.0% … +0.0% | +0.4% |
Sample size: 15 analogs, each at least 10 trading days apart (no double-counted overlapping events).
What happened after each historical match (20-day return)
| Date | Similarity | Regime | 20D outcome | 60D outcome |
|---|---|---|---|---|
| 2019-07-02 | 84/100 | Consolidation | -3.4% | -10.5% |
| 2017-07-11 | 82/100 | ✓ Consolidation | -3.7% | -9.5% |
| 2021-06-25 | 81/100 | Consolidation | +3.1% | +0.7% |
| 2019-07-18 | 80/100 | Consolidation | -10.7% | -8.6% |
| 2024-10-31 | 78/100 | ✓ Consolidation | +9.7% | +14.0% |
| 2017-08-03 | 78/100 | Consolidation | -3.1% | -14.6% |
| 2023-08-11 | 78/100 | Downtrend | -3.1% | -18.3% |
| 2018-10-19 | 78/100 | ✓ Consolidation | +4.3% | -5.1% |
| 2019-12-10 | 77/100 | Uptrend | -3.1% | -20.2% |
| 2021-11-24 | 77/100 | Consolidation | -1.3% | +9.9% |
| 2024-01-17 | 76/100 | Consolidation | +1.5% | -2.2% |
| 2025-02-25 | 75/100 | ✓ Consolidation | -8.5% | -4.9% |
| 2023-05-03 | 75/100 | Consolidation | -8.2% | -1.5% |
| 2024-09-12 | 75/100 | Consolidation | +2.7% | +7.1% |
| 2026-01-12 | 74/100 | Uptrend | +6.4% | -0.7% |
Every accepted match is compared to today across 6 domains (price structure, momentum, technical, volatility, volume, relative strength) using z-scored feature distances — no single indicator dominates. Matches within 10 trading days of each other count as one event, not independent evidence. Outcome rates use a Wilson confidence interval (never a raw percentage alone), the mean return is winsorized against extreme outliers, and "Analog Quality" separately captures sample size, data completeness, and regime match — distinct from raw similarity. Relative strength is measured against SPY and against XLV (this stock's sector).
Cross-stock analogs — real other companies, not this stock's own history.
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
50
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
56
Quality
42
Value
50
Momentum
33
Risk
50
Sentiment
100
Fundamental
48
Institutional
50
Stocks with a similar DNA right now
SCANNING HSIC...
Recent media coverage of Henry Schein has primarily centered on its stock performance and growth potential, with analysts highlighting its strong financial attributes and upward momentum. The company’s share price gains—including a 0.9% rise since its last earnings report—alongside positive total returns (29.4% over a year) and revenue growth, have drawn investor attention. Additionally, while not directly tied to Henry Schein, a related announcement noted its subsidiary, DermaSensor, securing four major U.S. partnerships to expand its AI-powered skin cancer detection technology. Overall, the focus remains on Henry Schein’s financial health and strategic expansions.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Henry Schein. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 1 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
21
🎯 Conviction (vs. Emotion)
36
Psychology
23
Fundamentals
48
Technical
33
Valuation
50
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+9%
Market Narrative
61
Fundamental Reality
36
Narrative Gap
+25
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
HSIC’s psychology is dominated by anchoring (41), as traders appear fixated on the 3% resistance gap, potentially limiting upside. Mild euphoria (25) and herding (32) suggest some speculative enthusiasm, but the narrative gap (66 vs. 36) indicates a disconnect between optimism and fundamentals. Overconfidence (3) is low, but the disconnect may fuel overreaction if resistance breaks. The key question: will traders anchor to resistance or pivot if momentum stalls?
Updated: 09/08/2026, 02:08 PM
What could change this?
👥 What the crowd believes
"Henry Schein (HSIC) reported earnings 30 days ago... alongside reported revenue and net income growth"
"Henry Schein stock performance snapshot... suggests momentum has been building... Is More Upside Still Available?"
"Henry Schein (HSIC) could produce exceptional returns... Growth Trajectory and Attractive Valuations Support Henry Schein’s (HSIC) Bullish Thesis"
"DermaSensor Inc. announced a major expansion... through a series of strategic partnerships to accelerate adoption"
📈 6D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 92/100
🔴 Weakest match
Benjamin Graham — 10/100
🗣️ Why do they disagree?
The methodologies here split sharply between cautious and neutral approaches, with only a few signaling even mild interest in HSIC. The most bullish signals come from Burton Malkiel & John Bogle’s efficient-market framework, which sees *mixed* potential but not enough edge to justify active picking over a passive index, and Charles Mackay’s crowd-based model, which flags *some* speculative excitement. Meanwhile, Samuel Armstrong Nelson’s mid-cycle stance and Jesse Livermore’s indecision suggest a lack of clear momentum, while Thorstein Veblen and Jack Schwager’s neutral scores imply no obvious growth-to-profit conversion. The divide widens further: Morgan Housel and Gerald Loeb see it as a *moderate* hold, but Howard Marks and his market-cycle variant treat it as a red flag—especially late-cycle risk. The most disciplined investors, like Benjamin Graham and Philip Fisher, outright reject it, citing valuation gaps and quality deficiencies, while Edgar Smith and Walter Bagehot warn of structural instability and liquidity risks. The spectrum reflects a stock that’s either too speculative for fundamentalists or too risky for cyclical strategists, with only a handful of frameworks tolerating it as a *tolerable* or *neutral* bet.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 92
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 65
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 51
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 49
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 48
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 48
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 46
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 45
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 43
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 42
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 24
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 21
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 18
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 17
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 15
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 10
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 300 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
31.1%
Operating Margin
5.0%
Net Margin
3.0%
EBITDA Margin
—
ROE
12.3%
ROA
3.5%
ROIC
—
EPS
$3.29
Cash
$156.00M
Total Debt
$764.00M
Current Ratio
1.38
Debt/Equity
0.96
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$28.03
Tangible Book Value per Share (Tangible NAV)
$19.24
Sentiment based on basic keywords (not AI) — 10 positive, 9 neutral, 1 negative out of the last 20 articles.
Yahoo · 16.9.2026
Yahoo · 16.9.2026
SeekingAlpha · 16.9.2026
SeekingAlpha · 15.9.2026
Yahoo · 9.9.2026
Business Wire · 9.9.2026
MT Newswires · 8.9.2026
Business Wire · 8.9.2026
Yahoo · 8.9.2026
Business Wire · 8.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 2.9.2026
Zacks · 2.9.2026
Yahoo · 2.9.2026
Simply Wall St. · 1.9.2026
Yahoo · 1.9.2026
Business Wire · 1.9.2026
Henry Schein (HSIC) currently has a StockIQ AI score of 50/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
HSIC currently scores 50/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
HSIC's technical score is 33/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: ATR: 2.0% of price; Price is above the 200-day average; +6.4% over the last 3 months relative to the index.
Based on the real signals StockIQ computed: Operating margin is eroding over time; Calmar: 0.22 (3y annualized return 5.4% / max drawdown 24.3%); Price is below the 50-day average.
StockIQ has no recorded dividend payment history for HSIC.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 2 purchases and 2 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Albertini Andrea | Disposition to the Company | 8.9.2026 | 3,984 | -3,984 | — |
| Albertini Andrea | Tax Withholding in Shares | 8.9.2026 | 603 | -603 | $88.86 |
| DANIEL WILLIAM K | Grant/Award from Employer | 12.6.2026 | 2,215 | +2,215 | — |
| DANIEL WILLIAM K | Grant/Award from Employer | 12.6.2026 | 7,641 | +2,215 | — |
| BERGMAN STANLEY M | Gift | 26.5.2026 | 253,279 | -50 | — |
| BERGMAN STANLEY M | Gift | 21.5.2026 | 50 | -50 | — |
| BERGMAN STANLEY M | Gift | 21.5.2026 | 253,279 | -50 | — |
| BERGMAN STANLEY M | Gift | 19.5.2026 | 1,040 | -1,040 | — |
| BERGMAN STANLEY M | Gift | 19.5.2026 | 253,329 | -1,040 | — |
| DANIEL WILLIAM K | Open Market Purchase | 11.5.2026 | 10,000 | +10,000 | $69.19 |
| DANIEL WILLIAM K | Open Market Purchase | 11.5.2026 | 20,000 | +10,000 | $69.19 |
| Popeck Thomas C | Open Market Sale | 19.3.2026 | 1,355 | -1,355 | $72.79 |
| Popeck Thomas C | Open Market Sale | 19.3.2026 | 86,182 | -1,355 | $72.79 |
| Ettinger Michael S | Gift | 17.3.2026 | 1,000 | -1,000 | — |
| Ettinger Michael S | Gift | 17.3.2026 | 112,208 | -1,000 | — |
| BERGMAN STANLEY M | Gift | 16.3.2026 | 400 | -400 | — |
| BERGMAN STANLEY M | Tax Withholding in Shares | 16.3.2026 | 50 | -50 | $74.61 |
| Ettinger Michael S | Tax Withholding in Shares | 16.3.2026 | 4,214 | -4,214 | $74.61 |
| Albertini Andrea | Tax Withholding in Shares | 16.3.2026 | 1,401 | -1,401 | $74.61 |
| MLOTEK MARK E | Tax Withholding in Shares | 16.3.2026 | 5,928 | -5,928 | $74.61 |
| Ettinger Michael S | Gift | 16.3.2026 | 1,300 | -1,300 | — |
| South Ronald N. | Tax Withholding in Shares | 16.3.2026 | 5,216 | -5,216 | $74.61 |
| Popeck Thomas C | Tax Withholding in Shares | 16.3.2026 | 587 | -587 | $74.61 |
| Sheehy Christine Zayac | Tax Withholding in Shares | 16.3.2026 | 463 | -463 | $74.61 |
| BERGMAN STANLEY M | Gift | 16.3.2026 | 254,419 | -400 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
8,141,621 shares short as of 2026-08-31 · vs. 6,301,135 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
74.6% of trading volume this week was short selling, vs. 64.7% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology